G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood

Bone Marrow Transplant. 1998 Dec:22 Suppl 5:S21-3.

Abstract

Since 1993 pediatric patients affected by high-risk Ewing sarcoma for the presence at onset of a large pelvic mass and/or metastatic disease, were enrolled in a national pilot study comprehensive, finally, of a high-dose chemotherapy (HDCT) procedure with hemopoietic stem cell support. The HDCT procedure considered as consolidation of the disease status obtained after the first-line therapy was followed by the reinfusion of granulokine colony-stimulating factor-primed (G-CSF) peripheral blood progenitor cell (PBPCT). Here we present the results in terms of treatment-related toxicity, hospitalization and rescue of the bone marrow function, in 17 pediatric patients enrolled in such a pilot protocol and submitted to HDCT and PBPCT at the end of first-line therapy.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Hematopoietic Stem Cell Mobilization*
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Male
  • Neutrophils / cytology
  • Pilot Projects
  • Platelet Count
  • Recurrence
  • Risk Factors
  • Sarcoma, Ewing / drug therapy
  • Sarcoma, Ewing / mortality
  • Sarcoma, Ewing / therapy*
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Granulocyte Colony-Stimulating Factor